Comparison of the efficacy of morning versus evening administration of olmesartan in uncomplicated essential hypertension

Chronobiology International

Volumn 24, Issue 1, 2007, Pages 171-181

  Smolensky, Michael H ^a   Hermida, Ramón C ^b   Portaluppi, Francesco ^c  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF VIGO   (Spain)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

Ambulatory blood pressure monitoring; Angiotensin receptor blocker; Chronopharmacology; Circadian rhythm; Hypertension; Olmesartan medoxomil

Indexed keywords

OLMESARTAN; PLACEBO;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, ORAL; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; CIRCADIAN RHYTHM; DIASTOLE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; SYSTOLE; TETRAZOLES; TREATMENT OUTCOME;

EID: 33847158433     PISSN: 07420528     EISSN: 15256073     Source Type: Journal    
DOI: 10.1080/07420520600969277     Document Type: Article

References (25)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Rocella EJ, and the National High Blood Pressure Education Coordinating Committee. (2003). The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289:2560-2571.
2. Chrysant SG, Marbury TC, Robinson TD. (2003). Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J. Hum. Hypertens. 17:425-432.
3. Fernández JR, Hermida RC. (1998). Inferential statistical method for analysis of nonsinusoidal hybrid time series with unequidistant observations. Chronobiol. Int. 15:191-204.
4. Fernández JR, Mojón A, Hermida RC. (2004). Comparison of parameters from rhythmometric models with multiple components on hybrid data. Chronobiol. Int. 21:469-484.
5. Guidelines Committee. (2003) European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21:1011-1053.
6. Hermida RC, Smolensky MH. (2004). Chronotherapy of hypertension. Curr. Opin. Nephrol. Hypertens. 13:501-505.
7. Hermida RC, Ayala DE, Fernández JR, Mojón A, Alonso I, Calvo C. (2002a). Modeling the circadian variability of ambulatorily monitored blood pressure by multiple-component analysis. Chronobiol. Int. 19:461-481.
8. Hermida RC, Calvo C, Ayala DE, Mojón A, López JE. (2002b). Relationship between physical activity and blood pressure in dipper and nondipper hypertensive patients. J. Hypertens. 20:1097-1104.
9. Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernández JR, Mojón A, López JE. (2003). Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 42:283-290.
10. Hermida RC, Ayala DE, Calvo C. (2005a). Administration time-dependent effects of antihypertensive treatment on the circadian pattern of blood pressure. Curr. Opin. Nephrol. Hypertens. 14:453-459.
11. Hermida RC, Calvo C, Ayala DE, Fernández JR, Covelo M, Mojón A, López JE. (2005b). Treatment of non-dipper hypertension with bedtime administration of valsartan. J. Hypertens. 23:1913-1922.
12. Hermida RC, Calvo C, Ayala DE, Mojón A, Rodr?́guez M, Chayán L, López JE, Fontao MJ, Soler R, Fernández JR. (2005c). Administration time-dependent effects of valsartan on ambulatory blood pressure in elderly hypertensive subjects. Chronobiol. Int. 22:755-776.
13. Labrecque G, Beauchamp D. (2003). Rhythms and pharmacokinetics. In: Redfern P, ed. Chronotherapeutics. London: Pharamceutical Press, pp. 75-110.
14. Laeis P, Puchler K, Kirch W. (2001). The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J. Hypertens. 19:S21-S32.
15. Lemmer B. (2000). Cardiovascular chronobiology and chronopharmacology. Importance of timing of dosing. In: White W.B, ed. Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics. Totowa, NJ: Humana Press, pp. 255-271.
16. Neutel JM. (2001). Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am. J. Cardiol. 87:37C-43C.
17. Neutel JM, Elliot WJ, Izzo JL, Chen CL, Masonson HN. (2002). Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. J. Clin. Hypertens. (Greenwich) 4:325-331.
18. O'Brien E, Staessen J. (1995). Normotension and hypertension as defined by 24-hour ambulatory blood pressure monitoring. Blood Press. 4:266-282.
19. O'Brien A, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P, on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. (2003). European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J. Hypertens. 21:821-848.
20. Oparil S, Silfani TN, Walker JF. (2005). Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am. J. Hypertens. 18(2Pt1):287-294.
21. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. (2005). Recommendations for blood pressure measurement in humans and experimental animals, Part 1: Blood pressure measurement in humans. Hypertension 45:142-161.
22. Portaluppi F, Smolensky MH. (2000). Circadian rhythm and environmental determinants of blood pressure regulation in normal and hypertensive conditions. In: White W.B, ed. Blood Pressure Monitoring in Cardiovascular Medicine and Therapeuticss. Totowa, NJ: Humana Press, pp. 79-118.
23. Smolensky MH, Hermida R, Portaluppi F, Haus E, Reinberg A. (2005). Chronotherapeutics in the treatment of hypertension. In: Oparil S, Weber MA (eds.) Hypertension: A Companion to Brenner and Rector's The Kidney, 2nd ed. Philadelphia: Elsevier Saunders, pp. 530-542.
24. Touitou Y, Smolensky MH, Portaluppi F. (2006). Ethics, standards, and procedures of animal and human chronobiology research. Chronobiol. Int. 23:1083-1096.
25. Witte K, Lemmer B. Rhythms and pharmacodynamics. In: Redfern P, ed. Chronotherapeutics. London: Pharamceutical Press, pp. 111-126.